A Study of Inclisiran in Participants With Homozygous Familial Hypercholesterolemia (HoFH)
Status:
Active, not recruiting
Trial end date:
2021-09-30
Target enrollment:
Participant gender:
Summary
This study is a Phase III, two-part (double-blind placebo-controlled/open-label) multicenter
study to evaluate safety, tolerability, and efficacy of inclisiran in subjects with
homozygous familial hypercholesterolemia (HoFH).